Table 1 Baseline characteristics of participants.

From: Improvement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: a double-blind randomized placebo-controlled trial

 

Placebo (n = 14)

Synbiotic (n = 13)

All (n = 27)

Women/men N (%)

12/2 (86/14)

11/2 (85/15)

23/4 (85/14)

Age (years old)

58 ± 7

58 ± 5

58 ± 6

Body weight (kg)

64.5 ± 11.4

69.1 ± 10.9

66.7 ± 11.2

BMI (kg/m2)

23.8 ± 3.2

24.7 ± 3.4

24.3 ± 3.3

SBP (mm Hg)

118.2 ± 15.8

118.2 ± 18.3

118.5 ± 16.7

DBP (mm Hg)

73.6 ± 6.6

75.8 ± 9.1

74.6 ± 7.8

ALAT (UI/l)

19.4 ± 6.1

24.8 ± 8.6

22.0 ± 7.7

ASAT (UI/l)

21.6 ± 4.2

24.1 ± 5.5

22.8 ± 4.9

Glycemia (g/l)

0.93 ± 0.10

0.97 ± 0.10

0.95 ± 0.10

Triglyceridemia (g/l)

0.96 ± 0.37

0.98 ± 0.43

0.97 ± 0.39

Cholesterolemia (g/l)

2.35 ± 0.40

2.38 ± 0.38

2.37 ± 0.39

  1. Values are means ± SD. Baseline data were analyzed by Mann–Whitney test for continuous variables (p > 0.05) and Fisher test for categorical variables (ratio women/men; p > 0.05).
  2. ALAT alanine aminotransferase, ASAT aspartate aminotransferase, BMI body mass index, DBP diastolic blood pressure, SBP systolic blood pressure.
Back to article page